NCT06206915View on ClinicalTrials.gov

Phase I Study of XZ120 in Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2027

Conditions
Advanced Malignancies
Interventions
DRUG

XZ120 injection

in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY